Two announcements landed on the same day, and neither of them is a contract. That is the first thing worth saying about D-Wave Quantum’s latest news cycle, which pairs an uncommitted partnership in Seoul with an award won by a customer in Japan. Investors who blur that distinction will misread both.
The stock offered no reward for the headlines. Shares slipped 4.2% on the day, though nothing in either release substantiates that move as a verdict on the LG CNS agreement. Chasing a single cause for a single session’s drift is less useful than asking what, if anything, the two items actually change.
What the LG CNS memorandum does and does not say
D-Wave and LG CNS disclosed a non-binding letter of intent to co-develop optimization applications for enterprise customers and to explore routes to market in South Korea and internationally. The pairing was unveiled at Qubits Asia, the company’s conference in Seoul, and D-Wave duly filed it as a mandatory disclosure.
Read past the word “strategic” and the operative term is “non-binding.” The two sides have sketched a framework for joint development and distribution — a door opened, not a sale booked. The more substantive story for the equity is directional: the emphasis falls on translating hardware capability into offerings that businesses will actually deploy, rather than on raw technical benchmarks.
That push toward commercial application has a second data point. On October 5, D-Wave announced a partnership with the University of Arkansas, where the Sam M. Walton College of Business is to host a quantum initiative focused on supply chains. A specific use case, yes — but again, an opening rather than evidence of revenue already earned.
Shionogi’s prize is a different kind of proof
The Japanese award validates work already completed, which sets it apart from a memorandum of understanding. Shionogi, a D-Wave customer, took first place in the quality-of-life category of Japan’s NEDO Quantum Computing Challenge, a result carrying a prize of 40 million yen.
The recognized research folded quantum computing into drug discovery. According to D-Wave, it included a peer-reviewed scientific study that applied the company’s annealing technology within a generative-AI model for molecular design. That is a higher evidentiary bar than a partnership press release — but it is not a commercial one. The prize honors the customer’s science; it should not be read as D-Wave revenue or as a new order.
The commercial yardstick: Como, SkyWater and a purchase option
Where the business case actually gets tested is in delivered systems and the contracts attached to them. Roughly two weeks ago, an Advantage2 machine was shipped to Como. Swiss Quantum Technology SA financed the system and acquired rights to half its capacity for five years, per company statements.
Should investors sell immediately? Or is it worth buying D-Wave Quantum?
That structure matters more than the shipment itself, because it ties hardware to financing and to multi-year usage rights — a way to separate technical capability from business consequence. An option to purchase the entire system exists alongside it, opening a further commercial path that has not yet been exercised. Treating that option as a completed sale would be getting ahead of the facts.
Manufacturing offers a parallel thread. The production collaboration with SkyWater Technology, extended about two weeks ago under a multi-year arrangement, speaks to execution. Separately, the two companies reported that a technology pilot project at SkyWater cut lot delays by as much as 30%. One concerns how systems get built; the other hints at practical utility. Neither, on its own, converts into a defined profit contribution.
Don’t misread the insider filings
Recent share movements by executives should not be filed under bearish signals. SEC disclosures covering transactions dated October 15 document shares withheld to settle tax obligations arising from the vesting of stock-based compensation. These were not open-market sales. That removes an easy misreading — while conceding nothing about future growth.
November 10 is where the numbers speak
The valuation debate now hinges on whether operational strides can be matched by financial results. The stock has lost 51% since the start of the year, which underscores the pressure on the multiple without answering the underlying question about commercial potential.
A firm catalyst is scheduled: third-quarter 2026 results are due before the market opens on November 10, with a webcast set for 8 a.m. Eastern Time. What matters there is the separation between results already booked, contractual arrangements in place, and deals that might come later. Investor conferences running from November 11 through December 3 will offer further chances to explain the business trajectory.
The bull case holds up as long as operational progress keeps company with hard financial evidence. Should the coming disclosures emphasize technical milestones without clarifying their financial weight, a more cautious read of the valuation would be warranted. Encouraging signals deserve attention — they just shouldn’t be asked to prove more than they do.
Ad
D-Wave Quantum Stock: Buy or Sell?! New D-Wave Quantum Analysis from October 28 delivers the answer:
The latest D-Wave Quantum figures speak for themselves: Urgent action needed for D-Wave Quantum investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 28.
D-Wave Quantum: Buy or sell? Read more here...
